Patients with chronic obstructive pulmonary disease showed lasting improvements for up to 2 years in anxiety and quality of life following 8 weeks of pulmonary rehabilitation.
Use of the novel composite end point known as COPDCompEx may be able to predict treatment effect on moderate to severe exacerbations of COPD, thus allowing shorter phase 2 clinical trials requiring fewer patients compared with current studies.
Fluticasone/salmeterol and budesonide/formoterol are common treatments for COPD; researchers investigated whether these treatments may be correlated with active tuberculosis risk.
The American Thoracic Society has released a new clinical practice guideline on the pharmacologic management of chronic obstructive pulmonary disease.
The 12-month history of acute exacerbations used to guide most COPD treatment relies on an unstable frequent exacerbator phenotype.